title: Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
authors.forename: Carlos I
authors.initials: CI
authors.lastname: Alatorre
authors.forename: Virginia
authors.initials: V
authors.lastname: Haynes
authors.forename: Douglas
authors.initials: D
authors.lastname: Faries
authors.forename: Himanshu
authors.initials: H
authors.lastname: Upadhyaya
authors.forename: Douglas
authors.initials: D
authors.lastname: Kelsey
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000191:economics*; D058647:Adrenergic alpha-2 Receptor Agonists / Q000191:economics*; D001289:Attention Deficit Disorder with Hyperactivity / Q000191:economics*; D005260:Female; D016316:Guanfacine / Q000191:economics*; D006801:Humans; D008297:Male; D011437:Propylamines / Q000191:economics*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058647:Adrenergic alpha-2 Receptor Agonists; D011437:Propylamines; D016316:Guanfacine